T he activation of B cells is initiated by engagement of their cognate Ag with the BCR, leading to a complex signal transduction cascade that can culminate in differentiation to Ab-secreting plasma cells (1) . To avoid detrimental autoimmune responses, differentiation of self from nonself Ag is essential. This differential recognition can be aided by coreceptors that modulate BCR signaling to either promote an immune response to nonself or suppress a response to self (2) . Two B cell inhibitory coreceptors are CD22 and Siglec-G, members of the siglec (sialic acid-binding Ig-like lectin) family, which recognize sialic acid-terminated glycans on glycoproteins and glycolipids (3) . Knockout mice deficient in both siglecs accumulate autoantibodies as they age, suggesting that they participate in maintaining B cell tolerance (4) . However, the precise roles of these two siglecs in regulating activation of B cells to self Ags are yet to be defined.
Receptors of the siglec family are differentially expressed on WBCs and regulate immune cell function (5) . The expression of CD22 is primarily B cell restricted. In contrast, a limited number of studies suggest that Siglec-G is more broadly expressed on B cells and myeloid cells (6, 7) . Whereas CD22 is conserved between mouse and human, Siglec-G is the murine ortholog of human Siglec-10. To date, no other siglecs have been detected on murine B cells (8) . Both CD22 and Siglec-G contain at least one ITIM on their cytoplasmic tail and are capable of inhibiting B cell receptor-mediated signaling (9) . A leading model for CD22-mediated suppression of BCR signaling is that proximity to the BCR leads to phosphorylation of its ITIMs by Src kinases, which recruits inhibitory phosphatases such as SHP-1 to dampen BCR signaling (10, 11) . Although Siglec-G has been less studied, Siglec-10 was shown to recruit SHP-1 in human B cells, suggesting that it may regulate BCR signaling by a mechanism similar to CD22 (12) .
In addition to its function in B cells, Siglec-G has also been shown to play an important role in dendritic cells by discriminating dangerassociated molecular patterns from pathogen-associated molecular patterns (PAMPs) (13) . Much like the model for siglec-mediated inhibition in B cells, this inhibition is based on proximity to the receptor. Unlike PAMPs, danger-associated molecular patterns were shown to be capable of simultaneously binding TLR4 and CD24. By virtue of a stable interaction between Siglec-G and CD24, Siglec-G becomes recruited to the TLR, which leads to dampened activation, compared with stimulation by PAMPs that cannot bind CD24. Interestingly, disruption of the sialic acid-mediated interaction of CD24 and Siglec-G by microbial sialidases exacerbated inflammation in an intestinal perforation model of sepsis (14) .
Insight into the role of Siglec-G on B cells has come from studying Siglec-G-deficient mice (6, 7) . These mice show an expansion of their B1 cell population in the pleural and peritoneal cavities (15) . B1 cells are responsible for the production of natural IgM and play an important role in the immune response to T-independent Ag such as bacterial polysaccharides (16) . After stimulation of the BCR by anti-IgM, B1 cells isolated from the peritoneal cavity of Siglec-Gdeficient mice show enhanced calcium signaling, whereas no significant difference was observed in splenic B2 cells (7) . This observation suggested a dominant role for Siglec-G in B1 cells, which appeared to be in line with a slightly higher expression on B1 cells, as judged by Western blot analysis. Therefore, it is believed that Siglec-G plays a dominant role in peritoneal B1 cells. Mice deficient in both Siglec-G and CD22 have an even higher number of B1 cells and, in contrast to the single knockout mice, develop spontaneous autoimmunity (4) . Cumulatively, these mouse genetic studies strongly suggest that CD22 and Siglec-G act in a complementary way to suppress B cell responses to self Ags.
Recent studies have shown that a nanoparticle decorated with a B cell-reactive Ag and a high-affinity ligand for CD22 is able to induce Ag-specific tolerance in mice (17, 18) . Copresentation of the Ag and CD22 ligand causes juxtaposition of CD22 with the BCR, leading to a tolerogenic circuit that culminates in apoptosis of the Ag-reactive B cell. On the basis of the specificity of the ligand for CD22, tolerance induction was mainly dependent on CD22, although one report showed partial dependence on Siglec-G (17). Thus, although several studies suggest that CD22 and Siglec-G cooperatively suppress B cell responses, an independent role for Siglec-G in B cell tolerance has not been demonstrated (4, 17, 18) .
To examine the potential of Siglec-G to induce B cell tolerance, we have developed a high-affinity ligand for Siglec-G that does not cross-react with CD22 and show that siglec-engaging toleranceinducing antigenic liposomes (STALs) displaying the Siglec-G ligand give rise to robust tolerance in mice toward both Tindependent and T-dependent Ags. Analysis of the initial events following stimulation of B cells with liposomes indicates that both B1 and B2 cells are equally capable of being inhibited by recruitment of Siglec-G to the BCR. This latter finding is in accordance with our finding that Siglec-G is expressed at equivalent levels in both B cell subtypes, as assessed using a newly developed anti-Siglec-G mAb. We also show that Siglec-G is expressed throughout B cell development, including pre-B cells before CD22 is expressed, suggesting that it may have a unique role in regulation of BCR signaling.
Materials and Methods

Animal studies
The Institutional Animal Care and Use Committee of The Scripps Research Institute (La Jolla, CA) approved all experimental procedures involving mice. CD22KO and Siglec-GKO mice, on a C57BL/6J background, were obtained from L. Nitschke 
Siglec-expressing cell lines
Myc-tagged Siglec-G-expressing BW5147 cells (American Type Culture Collection) were prepared as described previously (19) , and were used in this study as Siglec-G-expressing cells unless otherwise specified. Myc-tagged Siglec-15-expressing BW5147 cells and Myc-tagged Siglec-G-expressing L929 cells (American Type Culture Collection) were established by retroviral transduction using the plasmids pMXs-IG-Siglec-15-CD3z and pMXs-IG-Siglec-G-CD3z, as described previously (19) . Myc-tagged Siglec-Hexpressing BW5147 cells were prepared as described earlier (20) . Murine CD22-expressing cells were prepared by stable transfection of Chinese hamster ovary cells with a plasmid (pcDNA3.1-mCD22) encoding fulllength mCD22. Cells were sorted for expression of mCD22 high and maintained in F12/DMEM supplemented with 10% FBS and hygromycin as a selection marker. Other cell lines expressing murine siglecs in Chinese hamster ovary cells have been reported previously (21) .
Generation of a Siglec-G-specific mAb
A total of 20 million BW5147 cells expressing Myc-tagged Siglec-G were emulsified with CFA (Difco Laboratories) (38:62, v/v) before immunization.
Two female Lewis rats were immunized in the footpad with the immunogen (100 ml per footpad), followed by two boost injections of the cells emulsified with IFA at 10-d intervals. Animals were sacrificed 3 d after the last injection, and lymphocytes isolated from common iliac lymph nodes were washed three times with serum-free RPMI 1640 medium, and then fused at a 2:1 ratio with the mouse myeloma cell line Px63Ag.653 cells using polyethylene glycol 1500 (Roche). After the fusion, the cells were selected by hypoxanthine-aminopterin-thymidine selection. The medium for hybridoma culture was RPMI 1640 supplemented with 10% FCS, 2 mM glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, 1 mM nonessential amino acid, 1 mM sodium pyruvate, and 50 mM 2-ME, along with 2.5% Opti-Clone II-Hybridoma Cloning Factor (MP Biomedical). For the first screening, hybridoma culture supernatants were assayed for binding to the L929 cells expressing Myc-tagged Siglec-G by flow cytometry in conjunction with an anti-rat IgG secondary Ab. For the second screening, 293T cells were transfected with pcDNA3.1-Myc-His-Siglec-G, kindly provided by L. Nitschke (University of Erlangen, Erlangen, Germany). Hybridoma culture supernatants were assayed for binding to 293T cells transiently expressing Siglec-G by flow cytometry. Isotypes of the Abs were determined by flow cytometry, using biotinylated anti-Rat Ig Abs (BioLegend) followed by streptavidin-PE. Clone 4A6 generated in this study is of the rat IgG2 a k isotype. For large-scale preparation of the Ab, cells were grown 1 wk postconfluence, and the Ab in the culture supernatant was precipitated by ammonium sulfate (291 g/L), dialyzed against PBS, and purified by affinity chromatography using HiTrap Protein G HP column (GE Healthcare). Fractions containing the anti-Siglec-G Ab were dialyzed against PBS. Purified Abs were quantified by monitoring the absorbance at 280 nm. For conjugation, five equivalents of NHS-activated AF-647 (Invitrogen) was reacted with the Ab for 2 h at room temperature in sodium bicarbonate buffer (pH 8.5), followed by dialysis against PBS.
Cell preparation and flow cytometry
Single-cell suspensions of the spleen, bone marrow, and liver were prepared in HBSS containing 3% FCS. Spleen, bone marrow, and liver were ground, and the resulting cell suspension was filtered through a cell strainer (40 mm). Hepatic lymphocytes were purified by centrifugation using a 44%/67% Percoll Plus gradient (GE Healthcare). Peritoneal cells were obtained by peritoneal lavage in HBSS/3% FCS. After erythrocyte lysis, cells were stained for 20 min at 4˚C in HBSS containing 0.1% BSA and 2 mM EDTA (FACS buffer), with the respective Abs (BioLegend) at 1:200 dilution. The Siglec-G Ab was used at 3 mg/ml. Prior to staining, Fc receptors were blocked by anti-CD16/32 (BioLegend) at 1:200 dilution. Dead cells were gated out with 1 mg/ml propidium iodide. Data were acquired with an LSR II flow cytometer (BD Biosciences) and analyzed using FlowJo software (TreeStar).
Synthesis of siglec ligands
The CD22 ligand [9-biphenylacetyl-N-glycolylneuraminic acid-a2-6-galactose-b1-4-N-acetylglucosamine-b-ethylamine (69-BPA NeuGc)] was prepared as reported earlier (22) . The Siglec-G ligand [9-BPA-NeuGca2-3Galb1-4GlcAc-b-ethylamine, or 9-biphenylacetyl-N-glycolylneuraminic acid-a2-3-galactose-b1-4-N-acetylglucosamine-b-ethylamine (39-BPA NeuGc)] and the natural a2-3-sialoside NeuGca2-3Galb1-4GlcAc-b-ethylamine, or N-glycolylneuraminic acid-a2-3-galactose-b1-4-N-acetyl-glucosamine-b-ethylamine (39-NeuGc), were prepared using a similar strategy. Briefly, 9-amino-Nglycolylneuraminic acid and N-glycolylneuraminic acid were activated with CMP synthetase from Neisseria meningitidis. Subsequently, without isolation, the resulting CMP-activated sialic acids were reacted with Galb1-4GlcAc-b-ethlyazide, using Pasteurella multocida a2-3-sialyltransferase 1 (PMST1), to yield the respective trisaccharides (23). 9-Amino-NeuGca2-3Galb1-4GlcAc-b-ethyl azide was reacted with N-hydroxysuccinimideactivated biphenylacetyl acetic acid (BPA) using a solvent mixture of ImmunoResearch) were attached to PEG 2000 -DSPE by modifying lysine residues with a heterobifunctional crosslinker and subsequent coupling to maleimide-PEG 2000 -DSPE, as described previously (18) .
Preparation of liposomes
Liposomes were prepared by hydration of the lipids in PBS followed by sonication and extrusion through different filters down to a pore size of The Journal of Immunology100 nm, as described previously (18) . All liposomes were composed of a 60:35:5 molar ratio of distearoyl phosphatidylcholine (Avanti Polar Lipids), cholesterol (Sigma-Aldrich), and the respective pegylated lipid. The total concentration of the liposomes, as defined by the molarity of the lipids, was 5 mM. Fluorescent liposomes for binding experiments contained 1% or 4% siglec ligand and 0.1% Alexa 647. Liposomes for functional assays contained 0.5% anti-IgM or 0.33-0.1% HEL and 1 or 4% siglec ligand.
Liposome binding assays
Murine splenocytes and siglec-expressing cells were incubated with the respective fluorescent liposomes for 40 min at 4˚C in FACS buffer. Cells were washed, then stained with anti-CD19, and binding was assessed by flow cytometry.
B cell purification
B cells were purified from splenocytes by negative selection, using magnetic beads according to the manufacturer's protocol (Miltenyi Biotec). The purity of isolated cells was generally $ 99%.
Ca 2+ flux
Following preparation of single-cell suspensions of splenocytes for cells from the peritoneal cavity, cells were loaded with Indo-1 (Invitrogen), as described previously (7). Cells were stimulated with liposomes, and Indo-1 fluorescence was monitored by flow cytometry, as described in our previous publication (18) .
B cell proliferation assay and Western blotting
Purified IgM HEL B cells were stimulated with 5 uM liposomes for 3 min, and their activation was analyzed by Western blotting. For analysis of B cell proliferation, cells were first labeled with 1 uM CellTrace Violet (Invitrogen) prior to stimulation with liposomes. For all in vitro assays, the media consisted of RPMI 1640 supplemented with 10% FCS, 2 mM glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, 1 mM nonessential amino acid, 1 mM sodium pyruvate, and 50 mM 2-ME.
Immunizations and ELISA
Mice were injected i.p. or i.v. with liposomes displaying NP or HEL with or without siglec ligand. The liposomes were delivered in 200 ml PBS at 0.5 mM total lipid concentration. Whole blood (50 ml) was collected from mice via retro-orbital bleeds. NP-and HEL-specific Abs were determined by ELISA with NP(1)-BSA-coated (20 mg/ml) and HEL-coated (10 mg/ ml) MaxiSorp plates (Nunc), as described previously (18) . NP(1)-BSA was prepared as described earlier (24) . The titer was defined as the endpoint titer, which was the dilution of serum that achieved an absorbance 2-fold above background.
Results
Siglec-G is expressed throughout B cell differentiation
To quantitatively investigate cell surface expression of Siglec-G on murine leukocytes, we developed a mAb toward the extracellular portion of Siglec-G. The Ab shows strong specificity for Siglec-G, as highlighted by its lack of binding to cells from Siglec-G-deficient mice (Fig. 1A) . Among splenic leukocytes (Fig. 1B) , Siglec-G is expressed at highest levels on B cells and, to a lesser extent, on dendritic cells and a subset of macrophages (Fig. 1B) . Slight expression was also observed on neutrophils, and no expression was detected on T cells or NK cells. Of interest, evaluation of B cell subsets from the spleen, bone marrow, and the peritoneal cavity revealed a consistent expression of Siglec-G on all B cell subsets examined (Fig. 1C, 1D) . Notably, significant Siglec-G expression appears early on in B cell development, as early as pre-pro and immature B cells. Siglec-G expression remains at a constant level on germinal center and memory B cells, whereas no expression is observed on plasma cells (Supplemental Fig. 1A ). All subsets of splenic dendritic cells showed Siglec-G expression with the highest expression on CD11b + myeloid dendritic cells (Supplemental Fig.  1B) . In the liver, Siglec-G expression was found on B cells and macrophages ( Supplemental Fig. 1C ).
Specificity of a newly developed high-affinity glycan ligand for Siglec-G To evaluate the independent roles of CD22 and Siglec-G as regulators of BCR signaling, we set out to evaluate the ability of Siglec-G to induce tolerance by enforced coligation to the BCR, using nanoparticles that expressed both an Ag and a siglec ligand, which we have described as STALs. To investigate the impact of the B cell siglecs on BCR signaling, selective ligands for either siglec were required. Previously, a high-affinity and selective glycan ligand for CD22 (69-BPA NeuGc; Fig. 2A ) was described, but no equivalent ligand has been reported for Siglec-G (22). a2-6-Sialosides carrying a BPA group at the 9-position of the sialic acid (69-BPA NeuGc) show a 100-fold increase in affinity to CD22 compared with the natural, unsubstituted ligand. Because Siglec-G is known to be capable of binding a2-3-sialosides, whereas CD22 exhibits strict preference for a2-6-sialosides, we tested and fortuitously found that addition of the BPA substituent to an a2-3-sialosides results in a selective and high-affinity ligand for Siglec-G. Accordingly, the ligand 39- (Fig. 2B) . Furthermore, binding of the 39-BPA NeuGc liposomes to murine splenic B cells was completely dependent on Siglec-G, as no binding was detected in splenocytes from Siglec-G-deficient mice (Fig. 2C) . Conversely, 69-BPA NeuGc liposomes bound exclusively to CD22-expressing cells (Fig. 2B) .
Juxtaposition of Siglec-G and the BCR leads to inhibited Ca
2+ -signaling in both, B1 and B2 B cells
In previous studies, we and others (17, 18, 25) have demonstrated that enforced colocalization of the BCR and CD22, using nanoparticles displaying both a cognate Ag and CD22 ligands, leads to strong inhibition of B cell activation. With a Siglec-G-specific ligand in hand (39- BPA NeuGc), we set out to determine if the colocalization of BCR and Siglec-G also suppresses B cell activation, and ascertain the degree to which Siglec-G regulates BCR signaling in B1a cells and B2 cells. To this end, we prepared liposomes bearing an anti-IgM Fab fragment that serves as a surrogate Ag, either with or without the Siglec-G ligand (39-BPA NeuGc), to assess the influence of coligation of the BCR with Siglec-G. Stimulation of either B1a or B2 B cells with liposomes displaying anti-IgM alone led to strong B cell activation, as monitored by calcium flux. In contrast, stimulation with anti-IgMcontaining liposomes that also displayed 39-BPA NeuGc resulted in substantial suppression of Ca 2+ flux in both B cell populations (Fig. 3A, 3B) . Although B cells from Siglec-G-deficient mice showed generally diminished responses after stimulation with the liposomes, there was no influence of the Siglec-G ligand on activation of the B cells from Siglec-G-deficient mice. Most importantly, the inhibitory activity of the Siglec-G ligand was also prevented by preincubation of the cells with the anti-Siglec-G mAb, demonstrating that the 39-BPA NeuGc ligand exhibits its inhibitory function exclusively through Siglec-G (Supplemental Fig.  2) . Moreover, anti-IgM liposomes displaying the CD22-specific ligand (69-BPA NeuGc) suppressed activation, compared with liposomes displaying anti-IgM alone in a CD22-dependent manner in both B2 and B1a B cells (Fig. 3) . These results show that the 39-BPA NeuGc and 69-BPA NeuGc ligands are specific for Siglec-G and CD22, respectively, and that either siglec can independently suppress BCR activation when their ligands are incorporated into antigenic liposomes that enforce ligation of the siglec with the BCR.
Broad inhibition of B cell activation in an Shp-1-dependent manner
Although calcium flux is one hallmark of B cell activation, BCR signaling activates numerous signaling cascades that can initiate cell division and survival of B cells. To assess the impact of Siglec-G on the initial events in B cell activation, we analyzed cellular signaling pathways using phospho-specific Abs in conjunction with Western blotting. These experiments were carried out using splenic B cells from MD4 mice (26) , which are reactive toward HEL. We first verified in HEL-specific B cells that liposomes displaying HEL and Siglec-G ligand suppress Ca 2+ flux, compared with liposomes displaying HEL alone in a Siglec-G-dependent manner (Supplemental Fig. 3 ). Relative to liposomes displaying HEL alone, liposomes that additionally display the Siglec-G ligand suppressed phosphorylation (or degradation) of multiple BCR signaling events, including those that signal through MAPK, Erk, NF-kB, and Akt (Fig. 4A) . The inhibition of B cell signaling we observe is Shp-1 dependent because the activation of B cells from Shp-1-deficient (moth-eaten) mice is not inhibited by the Siglec-G ligand (Fig. 4B) . B cells from Shp-1-deficient mice contain a mixture of B1 and B2 cells. Therefore, the results suggest that Siglec-G exhibits its inhibitory function through Shp-1 in both B cell subpopulations. These results demonstrate that ligand-mediated recruitment of Siglec-G to the BCR strongly dampens both proximal and distal signaling components in the BCR signaling cascade and that this inhibition is dependent on Shp-1.
Siglec-G ligands reduce B cell proliferation and survival in vitro
We next determined the longer-term fate of the HEL-reactive MD4 cells stimulated with STALs. Fluorescently labeled B cells were cultured in vitro with liposomes, and proliferation of the cells was monitored by fluorescence dilution. Cells incubated with liposomes displaying HEL alone underwent robust proliferation, as assessed at day 4 (Fig. 5A, 5B) . Notably, all the cells exposed to liposomes displaying both HEL and 39-BPA NeuGc were activated and divided, but there was a pronounced diminishment in proliferation. Moreover, a significant reduction of live cells relative to cells stimulated with HEL alone (Fig. 5B) was noted. These effects were dependent on Siglec-G, as no difference was observed when Siglec-G-deficient MD4 B cells were stimulated with liposomes displaying Ag and Siglec-G ligand. Therefore, coligation of the BCR and Siglec-G leads to inhibited B cell proliferation and decreased survival, compared with stimulation by ligation of the BCR alone.
Liposomes displaying Siglec-G ligand and Ag induce tolerance in vivo
Copresentation of Ag and CD22 ligands on nanoparticles has been documented to induce Ag-specific tolerance in mice (17, 18) . On the basis of the ability of liposomes bearing the Siglec-G ligand to suppress BCR signaling in vitro, we set out to determine if Siglec-G could also independently induce tolerance in vivo. Accordingly, we investigated the ability of liposomal nanoparticles carrying the Siglec-G ligand to induce tolerance to exemplary T-independent and T-dependent Ags. The i.p. injection of immunogenic liposomes displaying the T-independent Ag NP resulted in reproducible production of IgM and IgG Abs, whereas liposomes that additionally displayed 39-BPA NeuGc had greatly reduced anti-NP titers, and failed to produce Ab upon subsequent challenge with the immunogenic liposomes 2 and 4 wk later (Fig. 6A , Supplemental Fig. 4A ). Similar results were obtained after i.v. administration of the liposomes (Supplemental Fig. 4B) .
Similarly, i.v. administration of immunogenic liposomes displaying the T-dependent Ag HEL induced a strong IgG 1 response, whereas only negligible amounts of anti-HEL Abs were produced after injection of liposomes with both HEL and 39-BPA NeuGc (Fig.  6B ). Subsequent challenges with HEL liposomes demonstrated that tolerance had been induced in the group of mice given STALs in the initial injection. The identical experiment was repeated in Siglec-G-deficient mice, and no significant difference in Ab titers between the two groups was observed, demonstrating that induction of tolerance is mediated by Siglec-G (Fig. 6B) .
To assess the relevance of Siglec-G-mediated tolerance to its natural function on B cells, we investigated tolerance induction by antigenic liposomes displaying a natural sialoside. The sialoside chosen for this study is 39-NeuGc, a terminal sequence commonly found on N-linked and O-linked glycans on many murine cell types. We find that even this natural ligand is capable of inducing tolerance, and it occurs in a primarily Siglec-G-dependent manner (Fig. 6C) . Therefore, recruitment of Siglec-G to the immunological synapse in B cells can induce tolerance in mice, and this may represent a natural tolerogenic mechanism that operates to maintain self-tolerance.
Discussion
In this article, we demonstrate that the two murine B cell siglecs, Siglec-G and CD22, can independently regulate BCR signaling, and can induce B cell tolerance when the Ag is presented in trans with siglec ligands that enforce ligation of the siglec with the BCR. An impediment for studying the role of trans ligands in regulating the function of Siglec-G has been the lack of a suitable high-affinity and selective ligand. In this study, we circumvent this need through the development of such a high-affinity glycan ligand for Siglec-G that does not cross-react with CD22 or any other murine siglec. Incorporation of this newly described Siglec-G ligand onto immunogenic liposomes clearly revealed that recruitment of Siglec-G to the immunological synapse inhibits B cell activation, as shown by calcium flux in an Shp-1-dependent manner, signaling components of the BCR, and proliferation. Therefore, we believe that enforced ligation of Siglec-G and the BCR, resulting from a membrane displaying both Ag and Siglec-G ligand, results in inhibition of B cell activation in a manner similar to that described previously for CD22.
In B cell proliferation assays, we noticed that not only was B cell activation inhibited by liposomes displaying Ag and 39-BPA NeuGc but also the number of live B cells was greatly reduced compared with B cells stimulated with Ag alone. This finding suggested that a tolerogenic circuit is induced, resembling the one we previously described by liposomes decorated with Ag and CD22 ligand. Indeed, STALs were able to induce robust tolerance in vivo toward both T-independent and T-dependent Ag. In contrast to WT mice, Siglec-G-deficient mice did not become tolerized, which clearly demonstrated the specificity of our observations.
Of interest, we discovered that antigenic liposomes displaying a natural a2-3-sialoside could also induce tolerance in a Siglec-Gdependent manner. We believe this may relate to a natural function for Siglec-G on B cells. Tolerization of B cells autoreactive for a cell surface Ag could be aided by Siglec-G, which will be recruited to the immunological synapse by a dense layer of sialic acid. The differential specificity of CD22 and Siglec-G is interesting in this regard. Outside the nervous system, there are two predominant linkages of sialic acid to underlying glyans: a2-3-and a2-6-sialosides. It is well known that the ratio of these two forms of sialic acid varies among different cell types, in large part owing to differential expression of the appropriate 2-6-and 2-3-sialyltransferases (27) (28) (29) (30) . For instance, hepatocytes and B cells have high levels of a2-6-sialosides owing to high expression of ST6Gal1. By extension, cell types that express ST6Gal1 at lower levels will have more a2-3-sialosides. As mentioned above, CD22 exhibits a strong preference for a2-6-over a2-3-sialosides, whereas Siglec-G clearly has the ability to bind a2-3-sialosides. Thus it will be of interest to determine if CD22 and Siglec-G act cooperatively to mediate peripheral B cell tolerance to autoreactive cell surface Ag through their combined ability to recognize a broader range of sialoside sequences than either siglec alone.
As a part of these studies, we used a recently developed platform for polyclonal stimulation of B cells, which are liposomes decorated with the Fab fragment of an anti-IgM-reactive Ab (18) . These were initially used to allow us to investigate both B2 and B1a B cell subtypes, because peritoneal B1a cells from MD4 mice do not express the IgM HEL transgene (31) . B1a cells constitute the main population of B1 cells in the peritoneal cavity and can be On the basis of evidence that Siglec-G-deficient mice have more B1a B cells, Siglec-G is believed to play a significant role in the development of this B cell subset. In particular, the expansion in Siglec-G-deficient mice is believed to be the result of hyperreactivity of B1a cells to BCR stimulation (4, 7) . In contrast, CD22-deficient mice show enhanced BCR-simulated B cell activation in B2 cells (32) (33) (34) (35) . Using the anti-IgM liposomes, we find that Siglec-G is capable of inhibiting B cell activation to a roughly equivalent extent in B1a cells from the peritoneal cavity and B2 cells from the spleen. This finding suggests that, besides its important function in B1a cells, Siglec-G is equally capable of inhibiting BCR signaling in splenic B2 cells upon encounter of its cognate Ag in the context of Siglec-G ligands. Whereas B1 and marginal zone B cells are thought to be the primary B cell subtypes responsible for immune responses toward T-independent type II Ags (36) , follicular B2 cells are more adapted for T-dependent immune responses (37) . Taken together with our finding that tolerance is induced toward both T-independent type-2 and Tdependent Ags, this observation suggests an important function for Siglec-G in maintaining tolerance toward sialylated Ags in various B cell compartments.
Consistent with the hypothesis of Siglec-G playing a role in various B cell compartments, we find equivalent cell surface expression of Siglec-G in B1a cells from the peritoneal cavity and B2 cells from the spleen. Furthermore, Siglec-G is developmentally expressed at constant levels throughout B cell development in the bone marrow, even before expression of IgM in immature B cells (Fig. 1) . This observation is consistent with the suggestion that Siglec-G influences the fate of B cells during early development, as evidenced by the enhanced number of B1a cells in the peritoneal cavity of Siglec-G-deficient mice (38) . In contrast to Siglec-G, CD22 is only weakly expressed in immature B cells before release into the periphery, and both CD22 expression and the Lyn/ CD22/Shp-1 regulatory access are upregulated in mature peripheral B cells (9, (39) (40) (41) . Thus, CD22 is not believed to play a role in central tolerance (39, 40, 42, 43) . On the basis of the constant expression of Siglec-G in the earliest stages of B cell development, we believe that studies on its potential contribution to central B cell tolerance are warranted.
In summary, we describe antigenic liposomes decorated with a high-affinity Siglec-G ligand as a novel tool to investigate the tolerogenic effect of Siglec-G toward Ags presented with sialosides on the same membrane. We find that Siglec-G is expressed at a constant level throughout B cell subsets and may contribute to maintaining peripheral B cell tolerance independently of, but in conjunction with, CD22.
